Tolerability and efficacy of aripiprazole in a case of psychotic anorexia nervosa comorbid with epilepsy and chronic renal failure

Eating and Weight Disorders

Volumn 12, Issue 3, 2007, Pages

  Aragona, Massimiliano ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Insegnamento di Filosofia Della Psicopatologia   (Italy)

Author keywords

Antipsychotics; Eating disorders; Pharmacotherapy; Psychosis; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; BUFLOMEDIL; CARBAMAZEPINE; ENALAPRIL; PIPEMIDIC ACID; RISPERIDONE; SERTRALINE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGGRESSION; ANOREXIA NERVOSA; ARTICLE; ASTHENIA; CASE REPORT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; COMORBIDITY; DELUSION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; EPILEPSY; FEMALE; HALLUCINATION; HUMAN; LOW DRUG DOSE; PSYCHOLOGICAL RATING SCALE; PSYCHOSIS; RAYNAUD PHENOMENON; SCALE FOR THE ASSESSMENT OF NEGATIVE AND POSITIVE SYMPTOM; SCORING SYSTEM; SEDATION; SIDE EFFECT; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE; WEIGHT CONTROL; WEIGHT GAIN; PSYCHOLOGICAL ASPECT;

ADULT; ANOREXIA NERVOSA; ANTIPSYCHOTIC AGENTS; COMORBIDITY; EPILEPSY; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; TREATMENT OUTCOME;

EID: 38449102020     PISSN: 11244909     EISSN: 15901262     Source Type: Journal    
DOI: 10.1007/BF03327643     Document Type: Article

References (23)

1. Bosanac P., Norman T., Burrows G., Beumont P.: Serotonergic and dopaminergic systems in anorexia nervosa: a role for atypical antipsychotics? Aust. N.Z.J. Psychiatry, 39, 146-153, 2005.
2. Powers P.S., Santana C.A., Bannon Y.S.: Olanzapine in the treatment of anorexia nervosa: an open label trial. Int. J. Eat. Disord., 32, 146-154, 2002.
3. Malina A., Gaskill J., McConaha C., Frank G.K., La Via M., Scholar M., Kaye W.H.: Olanzapine treatment of anorexia nervosa: a retrospective study. Int. J. Eat. Disord., 33, 234-237, 2003.
4. Barbarich N.C., McConaha C.W., Gaskill J., La Via M., Frank G.K., Achenbach S., Plotnicov K.H., Kaye W.H.: An open trial of olanzapine in anorexia nervosa. J. Clin. Psychiatry, 65, 1480-1482, 2004.
5. Mondraty N., Birmingham C.L., Touyz S., Sundakow V., Chapman L., Beumont P.: Randomized controlled trial of olanzapine in the treatment of cognitions in anorexia nervosa. Australas. Psychiatry, 13, 72-75, 2005.
6. Newman-Toker J.: Risperidone in anorexia nervosa. J. Am. Acad. Child. Adolesc. Psychiatry, 39, 941-942, 2000.
7. Bosanac P., Kurlender S., Norman T., Hallam K., Wesnes K., Manktelow T., Burrows G.: An open-label study of quetiapine in anorexia nervosa. Hum. Psychopharmacol., 22, 223-230, 2007.
8. Hudson J.I., Pope H.G. Jr., Jonas J.M.: Psychosis in anorexia nervosa and bulimia. Br. J. Psychiatry, 145, 420-423, 1984.
9. Mavrogiorgou P., Juckel G., Bauer M.: Recurrence of paranoid hallucinatory psychoses after beginning a fasting period in a patient with anorexia nervosa. Fortschr. Neurol. Psychiatr., 69, 211-214, 2001.
10. Blinder B.J., Cumella E.J., Sanathara V.A.: Psychiatric comorbidities of female inpatients with eating disorders. Psychosom. Med., 68, 454-462, 2006.
11. Andreasen N.C.: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, The University of Iowa, 1981.
12. Andreasen N.C.: Scale for the Assessment of Positive Symptoms (SAPS). Iowa City, The University of Iowa, 1984.
13. Jackson M., Williams P.V.: Unimaginable storms: a search for meaning in psychosis. London, Karnac Books, 1994.
14. Signer S.F., Benson D.F.: Three cases of anorexia nervosa associated with temporal lobe epilepsy. Am. J. Psychiatry, 147, 235-238, 1990.
15. Trummer M., Eustacchio S., Unger F., Tillich M., Flaschka G.: Right hemispheric frontal lesions as a cause for anorexia nervosa report of three cases. Acta Neurochir., 144, 797-801, 2002.
16. Fohlin L.: Body composition, cardiovascular and renal function in adolescent patients with anorexia nervosa. Acta Paediatr. Scand., 268 (Suppl.), 1-20, 1977.
17. Marinella M.A.: Raynaud's phenomenon and anorexia nervosa. South. Med. J., 88, 1279-1280, 1995.
18. Rustin M.H., Foreman J.C., Dowd P.M.: Anorexia nervosa associated with acromegaloid features, onset of acrocyanosis and Raynaud's phenomenon and worsening of chilblains. J. R. Soc. Med., 83, 495-496, 1990.
19. Luck P., Wakeling A.: Increased cutaneous vasoreactivity to cold in anorexia nervosa. Clin. Sci., 61, 559-567, 1981.
20. Pancheri P., Tarsitani L.: A new approach to antipsychotic therapy: a D2-5HT1A partial agonist. It. J. Psychopathol., 11, 96-119, 2005.
21. McQuade R.D., Stock E., Marcus R., Jody D., Gharbia N.A., Vanveggel S., Archibald D., Carson W.H.: A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J. Clin. Psychiatry, 65 (Suppl.18), 47-56, 2004.
22. Jody D., Saha A., Iwamoto T., Biswas D., Lin C-Y., Marcus R., McQuade R.: Meta-analysis of weight effects with aripiprazole. Eur. Neuropsychopharmacol., 12 (Suppl.3), 290, 2002.
23. Zhang J.Y., Kowal D.M., Nawoschik S.P., Lou Z., Dunlop J.: Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms. Biochem. Pharmacol., 71, 521-529, 2006.